To compare the safety and effectiveness of itraconazole oral solution to placebo in the treatment of a pulmonary aspergilloma. Aspergilloma is a "fungal ball" in the lungs caused by Aspergillus. The infection can spread from the lungs through the blood to other organs. Aspergilloma can be life-threatening; therefore, an effective treatment is needed...
Date First Received: May 18, 2000
Last Updated: November 11, 2005
Verified by: National Institute of Allergy and Infectious Diseases (NIAID), November 2005
Clinical Trial Phase: Phase 2 | Start Date:
Overall Status: Completed
Estimated Enrollment: 96
Brief Summary
Official Title: “A Multicenter, Prospective, Randomized, Double-Blind Clinical Trial Comparing Itraconazole Oral Solution in Cyclodextrin to Placebo in the Treatment of Aspergilloma”
Condition Keyword(s):
Intervention(s):
To compare the safety and effectiveness of itraconazole oral solution to placebo in the treatment of a pulmonary aspergilloma.
Aspergilloma is a "fungal ball" in the lungs caused by Aspergillus. The infection can spread from the lungs through the blood to other organs.
Aspergilloma can be life-threatening; therefore, an effective treatment is needed.
Study Type: Interventional
Study Design: Treatment, Double-Blind, Safety/Efficacy Study
Detailed Clinical Trial Description
Patients are randomly selected to receive itraconazole oral solution by mouth or the inactive placebo (oral cyclodextrin solution) twice daily for 12 months.
Intervention(s) in this Clinical Trial
- Drug: Itraconazole oral solution
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
You may be eligible for this study if you:
- Are 18 years of age or older.
- Have been diagnosed with aspergilloma within the last month.
- Have (or have a history of) at least one of the following:
- 1. positive test for Aspergillus species.
- 2. presence of antibodies to Aspergillus.
- Are willing to participate in the study for 2 full years.
- Are female and not pregnant.
- Are not breast-feeding.
- Agree to use barrier methods of birth control / contraception during the study and for 30 days after.
Exclusion Criteria:
You will not be eligible for this study if you:
- Have a history of allergy to triazole or imidazole drugs.
- Are unable to take oral medication.
- Are not expected to live for more than a month.
- Have had a lung biopsy indicating Aspergillus infection.
- Have had radiation therapy within the last 6 months.
- Require treatment with certain medications.
- Received amphotericin, amphotericin lipid formulation, fluconazole, or itraconazole in the two weeks prior to study entry.
- Received chemotherapy within the last 6 months.
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Additional Information
Information obtained from ClinicalTrials.gov on July 02, 2009
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00005668
Study ID Number: DMID MSG 37
ClinicalTrials.gov Identifier: NCT00005668
Health Authority: United States: Federal Government
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.